

Resource Summary Report

Generated by [dkNET](#) on Sep 7, 2026

KMS-20

RRID:CVCL_2990

Type: Cell Line

Proper Citation

RRID:CVCL_2990

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2990

Proper Citation: RRID:CVCL_2990

Description: Cell line KMS-20 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Plasma cell myeloma

Defining Citation: [PMID:15215163](#), [PMID:17171682](#), [PMID:17692805](#), [PMID:18700954](#), [PMID:19306352](#), [PMID:22460905](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:32123307](#)

Comments: Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KMS-20

Synonyms: KMS20, Kawasaki Medical School-20

Cross References: ArrayExpress:E-MTAB-2770, BioSample:SAMN03472431, BioSample:SAMN10988070, cancercellines:CVCL_2990, Cell_Model_Passport:SIDM01575, CGH-DB:23-1, CGH-DB:9135-4, Cosmic:2081393, DepMap:ACH-000426, GEO:GSM143350, GEO:GSM290297, GEO:GSM887223, GEO:GSM888297, IARC_TP53:28391, JCRB:JCRB1196, JCRB:NIHS0484, LiGeA:CCLE_068, PharmacDB:KMS20_766_2019, Progenetix:CVCL_2990, Wikidata:Q54900171

ID: CVCL_2990

Record Creation Time: 20220427T220705+0000

Record Last Update: 20260905T180944+0000

Ratings and Alerts

No rating or validation information has been found for KMS-20.

Warning: Discontinued: JCRB; NIHS0484

Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Tiwari PK, et al. (2026) An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. Cell reports, 45(6), 117464.

Nicosia L, et al. (2023) Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. Cancer cell, 41(12), 2136.

Cottini F, et al. (2022) Redefining CD56 as a Biomarker and Therapeutic Target in Multiple Myeloma. Molecular cancer research : MCR, 20(7), 1083.

Vannam R, et al. (2021) Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. Cell chemical biology, 28(4), 503.

Shirasaki R, et al. (2021) Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradable Oncoproteins. Cell reports, 34(1), 108532.